A Non-Interventional National Study in Pediatric Patients With Unexplained Enlarged Spleen (OPPUS)

Brief description of study

Primary Objective:

To assess prevalence of Gaucher disease (GD) diagnosed in pediatric patients presenting with unexplained splenomegaly (SMG) after exclusion of first intention-diagnoses (e.g. portal hypertension, haematological malignancy, hemolytic anemia, infection) based on clinical examination and routine biological tests (full blood count, reticulocytes, liver tests, abdominal ultrasound, Coombs test and Epstein Barr virus serology).

Secondary Objectives:

  • To describe the rate of each identified disease category and the rate of patients with no final diagnosis at the end of the study in pediatric patients with unexplained SMG after exclusion of first intention diagnoses
  • To describe the characteristics (clinical, lab, genetics) of all pediatric patients included in the study and to describe the characteristics subdivided by identified disease category and absence of final diagnosis at the end of the study

Detailed description of study

The planned duration of this study is 39 months, which includes 36 months of patient recruitment.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Gaucher Disease, Splenomegaly, Acid SphingoMyelinase Deficiency
  • Age: - 18 Years
  • Gender: Male or Female

Inclusion criteria:

  • Patient under the age of 18 years
  • Patient with unexplained SMG (SMG defined as a palpable spleen, already known or discovered for the first time) and who has undergone tests to eliminate obvious causes of SMG

Exclusion criteria:

        Patient with any obvious cause of SMG as described by clinical examination and/or lab or
        imaging test available in medical records and/or having been diagnosed with any of the
        following conditions:
          1. hemolytic anemia
          2. hematological malignancy
          3. portal hypertension
          4. infectious disease associated with SMG (Cytomegalovirus, Epstein Barr virus,
             leishmaniasis or other obvious infectious cause revealed by the medical history)
        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.

Updated on 22 Aug 2022 . Study ID: NCT04845958

Find a site

What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact